SOLUBLE CD30, TUMOR-NECROSIS-FACTOR (TNF)-ALPHA, AND TNF RECEPTORS INPRIMARY HIV-1 INFECTION - RELATIONSHIP WITH HIV-1 RNA, CLINICAL OUTCOME AND EARLY ANTIVIRAL THERAPY

Citation
Gp. Rizzardi et al., SOLUBLE CD30, TUMOR-NECROSIS-FACTOR (TNF)-ALPHA, AND TNF RECEPTORS INPRIMARY HIV-1 INFECTION - RELATIONSHIP WITH HIV-1 RNA, CLINICAL OUTCOME AND EARLY ANTIVIRAL THERAPY, Journal of biological regulators and homeostatic agents, 11(1-2), 1997, pp. 43-49
Citations number
37
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Biology,"Medicine, Research & Experimental
ISSN journal
0393-974X
Volume
11
Issue
1-2
Year of publication
1997
Pages
43 - 49
Database
ISI
SICI code
0393-974X(1997)11:1-2<43:SCT(AT>2.0.ZU;2-7
Abstract
The natural course of human immunodeficiency type 1 (HIV-1) infection varies considerably. The identification of laboratory disease markers has become critically important to patient management. This study, car ried out on 37 patients with primary HIV-1 infection (PHI), shows that , along with plasma HIV-1 RNA and CD4(+) T cell counts, evaluation of plasma levels of some immune activation markers (sCD30, TNF-alpha, and sTNFR-I) may help to identify patients at risk of a more rapid diseas e progression. suggesting that immune activation is among the factors who determine the rate of disease progression. Early combination antiv iral therapy significantly decreased levels of virus load and of immun e activation markers, suggesting that it may reduce the extent of immu ne activation through the suppression of HIV-1 replication. Among othe rs, sCD30 could be a more sensitive marker of immune activation, and i t might be also useful in the monitoring of the response to antiviral therapy.